DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
LY2452473
2
Small molecule
Investigational
Unknown
Unknown
Erectile Dysfunction; Prostatic Hyperplasia; Prostatic Neoplasms, Castration-Resistant
Androgen Receptor modulator
LY2452473
×
Maximum Phase:
2
First Approval:
None
UNII:
XKW9MYF94Y
Molecule Type:
Small molecule
Molecular Formula:
C22H22N4O2
Molecular Weight:
374.44
AlogP:
3.56
PSA:
79.94
HBD:
1.0
HBA:
#RotB:
4.0
Source:
COBALAMIN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Supplement
COBALAMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
8406EY2OQA
Molecule Type:
Small molecule
Molecular Formula:
C62H88CoN13O14P
Molecular Weight:
1329.37
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
CHOLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CHOLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H42O5
Molecular Weight:
422.61
AlogP:
3.84
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
4.0
Source:
GCS-100
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
GCS-100
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROLEDUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Blood group Rh(D) polypeptide inhibitor
ROLEDUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
Z4T52O86QV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABACAVIR HYDROXYACETATE
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
ABACAVIR HYDROXYACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
B3C7MG354B
Molecule Type:
Small molecule
Molecular Formula:
C16H20N6O3
Molecular Weight:
344.38
AlogP:
0.64
PSA:
128.18
HBD:
3.0
HBA:
#RotB:
6.0
Source:
PLEVITREXED
2
Small molecule
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Unknown
PLEVITREXED
×
Maximum Phase:
2
First Approval:
None
UNII:
L9P2881C3H
Molecule Type:
Small molecule
Molecular Formula:
C26H25FN8O4
Molecular Weight:
532.54
AlogP:
2.06
PSA:
170.11
HBD:
4.0
HBA:
#RotB:
10.0
Source:
FORODESINE HCL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FORODESINE HCL
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MGCD265
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MGCD265
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEGSUNERCEPT
2
Protein
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
TNF-alpha inhibitor
PEGSUNERCEPT
×
Maximum Phase:
2
First Approval:
None
UNII:
Q5I7SFZ853
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APITOLISIB
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms
PI3-kinase class I inhibitor
APITOLISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
1C854K1MIJ
Molecule Type:
Small molecule
Molecular Formula:
C23H30N8O3S
Molecular Weight:
498.61
AlogP:
0.9
PSA:
133.83
HBD:
2.0
HBA:
#RotB:
5.0
Source:
RO-24-7429
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 Tat protein antagonist
RO-24-7429
×
Maximum Phase:
2
First Approval:
None
UNII:
MLW2GKK8LI
Molecule Type:
Small molecule
Molecular Formula:
C14H13ClN4
Molecular Weight:
272.74
AlogP:
2.77
PSA:
52.54
HBD:
2.0
HBA:
#RotB:
1.0
Source:
SCH-900271
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Hydroxycarboxylic acid receptor 2 agonist
SCH-900271
×
Maximum Phase:
2
First Approval:
None
UNII:
G2283XQ6VJ
Molecule Type:
Small molecule
Molecular Formula:
C14H16N2O4
Molecular Weight:
276.29
AlogP:
1.29
PSA:
95.93
HBD:
2.0
HBA:
#RotB:
4.0
Source:
SIMLUKAFUSP ALFA
2
Protein
Investigational
Unknown
Unknown
Carcinoma, Renal Cell; Melanoma
Fibroblast activation protein alpha binding agent
SIMLUKAFUSP ALFA
×
Maximum Phase:
2
First Approval:
None
UNII:
FL08SGO9XA
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROZROLIMUPAB
2
Unknown
Investigational
Unknown
Unknown
Purpura, Thrombocytopenic, Idiopathic
Blood group Rh(D) polypeptide inhibitor
ROZROLIMUPAB
×
Maximum Phase:
2
First Approval:
None
UNII:
S134V96RPQ
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KY-1005
2
Unknown
Investigational
Unknown
Unknown
Immune System Diseases; Dermatitis, Atopic
Tumor necrosis factor ligand superfamily member 4 inhibitor
KY-1005
×
Maximum Phase:
2
First Approval:
None
UNII:
YZ6BH6TN8P
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AFELETECAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
DNA topoisomerase I stabiliser
AFELETECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
IX0QAD6RD2
Molecule Type:
Small molecule
Molecular Formula:
C45H49N7O11S
Molecular Weight:
895.99
AlogP:
2.95
PSA:
237.48
HBD:
6.0
HBA:
#RotB:
13.0
Source:
BURAPITANT
2
Small molecule
Investigational
Unknown
Unknown
Urinary Bladder, Overactive
Neurokinin 1 receptor antagonist
BURAPITANT
×
Maximum Phase:
2
First Approval:
None
UNII:
E35SK332MS
Molecule Type:
Small molecule
Molecular Formula:
C31H35Cl2F6N3O3
Molecular Weight:
682.53
AlogP:
6.94
PSA:
75.87
HBD:
1.0
HBA:
#RotB:
8.0
Source:
DEUTARSERINE
2
Small molecule
Investigational
Unknown
Unknown
Schizophrenia
Unknown
DEUTARSERINE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C3H7NO3
Molecular Weight:
106.1
AlogP:
-1.61
PSA:
83.55
HBD:
3.0
HBA:
#RotB:
2.0
Source:
BAY-1093884
2
Unknown
Investigational
Unknown
Unknown
Hemophilia A; Hemophilia B
Tissue factor pathway inhibitor inhibitor
BAY-1093884
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
R-112
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Tyrosine-protein kinase SYK inhibitor
R-112
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELTOPRAZINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ELTOPRAZINE
×
Maximum Phase:
2
First Approval:
None
UNII:
510M006KO6
Molecule Type:
Small molecule
Molecular Formula:
C12H16N2O2
Molecular Weight:
220.27
AlogP:
0.87
PSA:
33.73
HBD:
1.0
HBA:
#RotB:
1.0
Source:
REVAMILAST
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Asthma
Unknown
REVAMILAST
×
Maximum Phase:
2
First Approval:
None
UNII:
30LE65637T
Molecule Type:
Small molecule
Molecular Formula:
C18H9Cl2F2N3O4
Molecular Weight:
440.19
AlogP:
4.77
PSA:
91.3
HBD:
1.0
HBA:
#RotB:
4.0
Source:
BI-836826
2
Unknown
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse
Leukocyte antigen CD37 inhibitor
BI-836826
×
Maximum Phase:
2
First Approval:
None
UNII:
LB090AB8DB
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOZULERISTIDE
2
Protein
Investigational
Unknown
Unknown
Breast Neoplasms; Glioma; Sarcoma; Skin Neoplasms; Central Nervous System Neoplasms
Unknown
TOZULERISTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
835UH424TU
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALAGEBRIUM CHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Cardiovascular Diseases; Heart Failure; Hypertension
Unknown
ALAGEBRIUM CHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
79QS8K2877
Molecule Type:
Small molecule
Molecular Formula:
C13H14ClNOS
Molecular Weight:
267.78
AlogP:
2.54
PSA:
20.95
HBD:
0.0
HBA:
#RotB:
3.0
Source:
FULACIMSTAT
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Heart Failure; Myocardial Infarction
Chymase inhibitor
FULACIMSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
VIR72PP4ZU
Molecule Type:
Small molecule
Molecular Formula:
C23H16F3N3O6
Molecular Weight:
487.39
AlogP:
2.7
PSA:
116.44
HBD:
1.0
HBA:
#RotB:
3.0
Source:
ENOBLITUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma; Carcinoma, Squamous Cell; Prostatic Neoplasms, Castration-Resistant
CD276 antigen cross-linking agent
ENOBLITUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
M6030H73N9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACRIDINE
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Lung Neoplasms
DNA disrupting agent
ACRIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
42NI1P5Q1X
Molecule Type:
Small molecule
Molecular Formula:
C13H9N
Molecular Weight:
179.22
AlogP:
3.39
PSA:
12.89
HBD:
0.0
HBA:
#RotB:
0.0
Source:
ROVAZOLAC
2
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic
Unknown
ROVAZOLAC
×
Maximum Phase:
2
First Approval:
None
UNII:
W51K389XIL
Molecule Type:
Small molecule
Molecular Formula:
C21H19F3N2O4S
Molecular Weight:
452.45
AlogP:
4.2
PSA:
78.26
HBD:
0.0
HBA:
#RotB:
6.0
Source:
LY2828360
2
Small molecule
Investigational
Unknown
Unknown
Osteoarthritis, Knee
Cannabinoid CB2 receptor agonist
LY2828360
×
Maximum Phase:
2
First Approval:
None
UNII:
O12H7VFU6P
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LISOFYLLINE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1
Unknown
LISOFYLLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
L1F2Q2X956
Molecule Type:
Small molecule
Molecular Formula:
C13H20N4O3
Molecular Weight:
280.33
AlogP:
-0.02
PSA:
82.05
HBD:
1.0
HBA:
#RotB:
5.0
Source:
REMLARSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Keloid
Unknown
REMLARSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
X2MD0LH19A
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CELGOSIVIR
2
Small molecule
Investigational
Unknown
Unknown
Dengue; Hepatitis C, Chronic
Alpha glucosidase inhibitor
CELGOSIVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
895VG117HN
Molecule Type:
Small molecule
Molecular Formula:
C12H21NO5
Molecular Weight:
259.3
AlogP:
-1.13
PSA:
90.23
HBD:
3.0
HBA:
#RotB:
3.0
Source:
VRC-01
2
Unknown
Investigational
Unknown
Unknown
HIV Infections
Unknown
VRC-01
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
195
196
197
198
199
200
201
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA